US5718893A
(en)
*
|
1984-04-15 |
1998-02-17 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
US5359035A
(en)
*
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
US6150328A
(en)
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
US5349052A
(en)
*
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
GB8824591D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
WO1990006952A1
(en)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9107846D0
(en)
*
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
EP0458064B1
(de)
*
|
1990-05-04 |
1998-02-25 |
American Cyanamid Company |
Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
|
US5951972A
(en)
*
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
ATE167896T1
(de)
*
|
1990-08-29 |
1998-07-15 |
Genetics Inst |
Aus mehreren domänen bestehende hämatopoese- stimulatoren
|
EP0503050A4
(en)
*
|
1990-09-28 |
1994-07-06 |
Ortho Pharma Corp |
Hybrid growth factors
|
AU654563B2
(en)
*
|
1991-07-24 |
1994-11-10 |
Imperial Chemical Industries Plc |
Proteins
|
JPH05271279A
(ja)
*
|
1991-08-07 |
1993-10-19 |
Takeda Chem Ind Ltd |
ヒト副甲状腺ホルモンムテインおよびその製造法
|
DE69233022T2
(de)
|
1991-11-04 |
2004-02-12 |
Genetics Institute, LLC, Cambridge |
Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
|
AU666914B2
(en)
*
|
1991-12-10 |
1996-02-29 |
Tanox Biosystems, Inc. |
Cytokines with an unpaired cysteine residue and conjugates thereof
|
US5578496A
(en)
*
|
1991-12-19 |
1996-11-26 |
Board Of Regents, Baylor College Of Medicine |
Detection of autoantibodies associated with the disease myasthenia gravis
|
WO1993012145A1
(en)
*
|
1991-12-19 |
1993-06-24 |
Baylor College Of Medicine |
Pva or peg conjugates of peptides for epitope-specific immunosuppression
|
US5705362A
(en)
*
|
1992-05-25 |
1998-01-06 |
Gist-Brocades, N.V. |
Modified signal sequences
|
US5772992A
(en)
*
|
1992-11-24 |
1998-06-30 |
G.D. Searle & Co. |
Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
|
US5738849A
(en)
*
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
US6403076B1
(en)
|
1992-11-24 |
2002-06-11 |
S. Christopher Bauer |
Compositions for increasing hematopoiesis with interleukin-3 mutants
|
US6361976B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
|
US6153183A
(en)
*
|
1992-11-24 |
2000-11-28 |
G. D. Searle & Company |
Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
|
US5604116A
(en)
|
1992-11-24 |
1997-02-18 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
|
AU5748994A
(en)
*
|
1992-12-16 |
1994-07-04 |
Board Of Regents, The University Of Texas System |
Potent and specific chemically-conjugated immunotoxins
|
US5581476A
(en)
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5420019A
(en)
*
|
1993-02-02 |
1995-05-30 |
Xoma Corporation |
Stable bactericidal/permeability-increasing protein muteins
|
US5501962A
(en)
*
|
1993-06-21 |
1996-03-26 |
G. D. Searle & Co. |
Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
JPH09504174A
(ja)
*
|
1993-10-29 |
1997-04-28 |
インサイト ファーマシューティカルズ,インク. |
プロテアーゼネキシン1変異体を含むキメラ蛋白
|
EP0728013A4
(de)
*
|
1993-11-10 |
1999-09-15 |
Jackson H M Found Military Med |
Zusammensetzung und methode zur stimmulierung der antikoerperfreisetzung durchb - lymphozyten
|
ATE319823T1
(de)
|
1993-12-07 |
2006-03-15 |
Inst Genetics Llc |
Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
|
US20030220233A1
(en)
|
1994-01-24 |
2003-11-27 |
Neorx Corporation |
Radiolabeled annexins
|
US5968477A
(en)
*
|
1994-01-24 |
1999-10-19 |
Neorx Corporation |
Radiolabeled annexin conjugates with hexose and a chelator
|
US5536495A
(en)
*
|
1994-04-15 |
1996-07-16 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
EP0756494A1
(de)
*
|
1994-05-24 |
1997-02-05 |
Amgen Boulder Inc. |
Modifizierte insulinähnliche-wachstumsfaktore
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
EP0785276A4
(de)
*
|
1994-09-29 |
2002-01-09 |
Ajinomoto Kk |
Modifizierung eines peptids und eines proteins
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5846770A
(en)
*
|
1994-11-22 |
1998-12-08 |
Genetics Institute, Inc. |
DNA molecules encoding human chordin
|
US5747027A
(en)
*
|
1995-04-07 |
1998-05-05 |
The Regents Of The University Of California |
BH55 hyaluronidase
|
US6184344B1
(en)
*
|
1995-05-04 |
2001-02-06 |
The Scripps Research Institute |
Synthesis of proteins by native chemical ligation
|
US6017523A
(en)
*
|
1995-06-06 |
2000-01-25 |
G.D. Searle & Co. |
Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
|
US5830761A
(en)
*
|
1995-06-07 |
1998-11-03 |
Genetics Institute, Inc. |
Medium and methods for culturing mammalian cho cells
|
US5763196A
(en)
*
|
1996-01-26 |
1998-06-09 |
Boehringer Mannheim Corporation |
Assays using cross-linked polypeptide fragments of β-galactosidase
|
ES2170937T3
(es)
*
|
1996-01-26 |
2002-08-16 |
Roche Diagnostics Corp |
Agentes de reticulacion bis-maleimido.
|
US5976857A
(en)
*
|
1996-01-26 |
1999-11-02 |
Boehringer Mannheim Corporation |
Cross-linked polypeptide fragments of β-galactosidase
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
JP4410852B2
(ja)
*
|
1996-08-02 |
2010-02-03 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
単一の共有結合n末端水溶性ポリマーを有するポリペプチド
|
US6743422B1
(en)
|
1996-10-15 |
2004-06-01 |
Amgen, Inc. |
Keratinocyte growth factor-2 products
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
JP2001513754A
(ja)
|
1996-12-06 |
2001-09-04 |
アムジェン インコーポレイテッド |
Tnf媒介疾患を処置するためのtnf結合タンパク質を使用する組み合わせ治療
|
BR9606270A
(pt)
*
|
1996-12-18 |
1998-09-22 |
Univ Minas Gerais |
Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
|
ATE258599T1
(de)
|
1997-02-21 |
2004-02-15 |
Genentech Inc |
Antikörperfragment-polymerkonjugate
|
US7122636B1
(en)
*
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US5935852A
(en)
*
|
1997-07-03 |
1999-08-10 |
Genetics Institute, Inc. |
DNA molecules encoding mammalian cerberus-like proteins
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
CA2296770A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
AU743905B2
(en)
|
1997-08-14 |
2002-02-07 |
Regents Of The University Of California, The |
Fluorescent amyloid abeta peptides and uses thereof
|
ATE267215T1
(de)
|
1997-12-08 |
2004-06-15 |
Lexigen Pharm Corp |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
US7005504B2
(en)
*
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
CZ298579B6
(cs)
|
1998-04-28 |
2007-11-14 |
Applied Research Systems Ars Holding N. V. |
Konjugát polyolu a interferonu-beta
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
EE05201B1
(et)
*
|
1998-10-16 |
2009-08-17 |
Biogen Idec Ma Inc. |
Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
IL144259A0
(en)
*
|
1999-01-14 |
2002-05-23 |
Bolder Biotechnology Inc |
Methods for making proteins containing free cysteine residues
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
KR100689212B1
(ko)
*
|
1999-01-29 |
2007-03-09 |
암겐 인코포레이티드 |
Gcsf 결합체
|
US6727224B1
(en)
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
EP1198565A1
(de)
*
|
1999-07-07 |
2002-04-24 |
Maxygen Aps |
Verfahren zur herstellung von modifizierten polypeptiden
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
JP4703926B2
(ja)
|
1999-10-15 |
2011-06-15 |
ジェネティクス インスティテュート,エルエルシー |
骨形成蛋白をデリバリーするためのヒアルロン酸の処方
|
EP1228214A2
(de)
*
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
US6646110B2
(en)
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
US6831158B2
(en)
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US6602498B2
(en)
|
2000-02-22 |
2003-08-05 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
AU2001289307A1
(en)
*
|
2000-04-06 |
2001-10-23 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
JP2003533681A
(ja)
|
2000-05-15 |
2003-11-11 |
テカン・トレーディング・アクチェンゲゼルシャフト |
ミクロ流体装置および細胞ベースの分析を実行する方法
|
DE60129432T2
(de)
|
2000-05-16 |
2008-04-17 |
Bolder Biotechnology, Inc., Louisville |
Verfahren zur rückfaltung von proteinen mit freien cysteinresten
|
US20040038878A1
(en)
|
2000-08-04 |
2004-02-26 |
Masahiko Tanikawa |
Injectable protein formulations
|
ES2644275T3
(es)
|
2000-08-11 |
2017-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Preparaciones estabilizadas que contienen anticuerpos
|
AU2001282607B2
(en)
|
2000-09-01 |
2006-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Solution preparations stabilized over long time
|
MXPA03002046A
(es)
|
2000-09-08 |
2003-07-24 |
Massachusetts Inst Technology |
Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
|
JP2004518621A
(ja)
*
|
2000-09-08 |
2004-06-24 |
グリフォン セラピューティクス,インコーポレーテッド |
「擬似」天然型化学的ライゲーション
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
CA2438652A1
(en)
|
2001-02-19 |
2002-09-06 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
|
KR20090010127A
(ko)
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
|
ES2869895T3
(es)
|
2001-03-09 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Método de purificación de proteínas
|
US7235638B2
(en)
*
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
ES2432967T3
(es)
|
2001-03-22 |
2013-12-05 |
Novo Nordisk Health Care Ag |
Derivados del Factor VII de coagulación
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
EP1382964A4
(de)
|
2001-04-17 |
2009-06-10 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur tensid-quantifizierung
|
DK1383785T3
(da)
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
JP2002346015A
(ja)
*
|
2001-05-28 |
2002-12-03 |
Hiroaki Yoshiike |
スイング診断装置
|
ATE393573T1
(de)
|
2001-06-01 |
2008-05-15 |
Wyeth Corp |
Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
|
TWI267378B
(en)
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
US20040186051A1
(en)
|
2001-10-02 |
2004-09-23 |
Kelley Robert F |
Apo-2 ligand variants and uses thereof
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
EP1497634A4
(de)
*
|
2001-11-08 |
2007-02-07 |
Applied Research Systems |
Proteinknoten
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
AU2002351746A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Maxygen Aps |
Erythropoietin conjugates
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
EP1490402A4
(de)
*
|
2002-03-20 |
2007-05-02 |
Biopolymed Inc |
Herstellung von am cysteinrest stöchiometrisch mit biokompatiblen polymeren konjugiertem g-csf
|
US20040014662A1
(en)
*
|
2002-05-08 |
2004-01-22 |
Per Lindquist |
Modulation of neural stem cells and neural progenitor cells
|
EP1837031B1
(de)
*
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Methoden und Kompositionen um Diabetes zu behandeln
|
DE60336555D1
(de)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
Pegylierte glykoformen von faktor vii
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
CA2497364C
(en)
|
2002-09-11 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification method
|
US20060177894A1
(en)
*
|
2002-11-08 |
2006-08-10 |
Moyle William R |
Protein knobs
|
WO2004055056A1
(en)
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
BR0317752A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
|
EP1667708B9
(de)
*
|
2002-12-26 |
2012-10-31 |
Mountain View Pharmaceuticals, Inc. |
INTERFERON-BETA-1b POLYETHYLENEGLYKOL-KONJUGATE MIT ERHÖHTER IN VITRO BIOLOGISCHER WIRKSAMKEIT
|
US7695723B2
(en)
|
2002-12-31 |
2010-04-13 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
US7785601B2
(en)
|
2002-12-31 |
2010-08-31 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
DE60329627D1
(de)
*
|
2002-12-31 |
2009-11-19 |
Nektar Therapeutics Al Corp |
Hydrolysestabile maleimidendgruppen-enthaltende polymere
|
US7432331B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
KR100512483B1
(ko)
*
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
WO2004100997A2
(en)
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Spacer moiety for poly(ethylene glycol) -modified peptides
|
AU2004238870B8
(en)
|
2003-05-12 |
2010-04-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
DE602004028725D1
(de)
|
2003-05-12 |
2010-09-30 |
Affymax Inc |
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
|
KR20120094001A
(ko)
|
2003-05-12 |
2012-08-23 |
아피맥스, 인크. |
에리스로포이에틴 수용체에 결합하는 펩티드
|
EP3593820A1
(de)
|
2003-05-23 |
2020-01-15 |
Nektar Therapeutics |
Peg-derivate enthaltend zwei peg ketten
|
CN1826131A
(zh)
|
2003-05-30 |
2006-08-30 |
森托科尔公司 |
利用转谷氨酰胺酶形成新的促红细胞生成素缀合物
|
US7700097B2
(en)
*
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
WO2005023862A2
(en)
*
|
2003-08-07 |
2005-03-17 |
Zymogenetics, Inc. |
Homogeneous preparations of il-28 and il-29
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EP1663188B1
(de)
*
|
2003-09-12 |
2016-08-10 |
Newron Sweden AB |
Behandlunge von erkrankungen des nervensystems
|
SI1675608T1
(sl)
|
2003-09-12 |
2007-08-31 |
Wyeth Corp |
Injektibilne trdne paličice kalcijevega fosfata za dajanje osteogenih proteinov
|
US7220407B2
(en)
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
AU2004297228A1
(en)
|
2003-12-03 |
2005-06-23 |
Nektar Therapeutics Al, Corporation |
Method of preparing maleimide functionalized polymers
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
EP1586334A1
(de)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF Konjugate mit PEG
|
EP1771197A2
(de)
*
|
2004-06-30 |
2007-04-11 |
Egen Corporation |
Pegyliertes interferon-alpha-1b
|
US7579444B2
(en)
|
2004-06-30 |
2009-08-25 |
Nektar Therapeutics Al, Corporation |
Polymer-factor IX moiety conjugates
|
US7511016B2
(en)
*
|
2004-07-07 |
2009-03-31 |
Mosamedix B.V. |
Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
JP2008513027A
(ja)
*
|
2004-09-17 |
2008-05-01 |
バイオマリン ファーマシューティカル インコーポレイテッド |
フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
|
EP1814573B1
(de)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
CA2586365A1
(en)
|
2004-11-05 |
2006-05-26 |
Northwestern University |
Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
|
PH12014500352A1
(en)
|
2004-11-12 |
2015-07-20 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
JP4951527B2
(ja)
|
2005-01-10 |
2012-06-13 |
バイオジェネリックス アーゲー |
糖peg化顆粒球コロニー刺激因子
|
WO2006089228A2
(en)
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
CN100381420C
(zh)
*
|
2005-03-23 |
2008-04-16 |
于勇海 |
一种n-乙酰基半胱氨酸衍生物与应用
|
EP2386571B1
(de)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
|
EP1885403B1
(de)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethylenglykol)-Konjugate von Lysostaphin
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
EP2975135A1
(de)
*
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glykopegylierter Faktor IX
|
AU2006254543A1
(en)
|
2005-06-01 |
2006-12-07 |
Maxygen Holdings Ltd. |
PEGylated G-CSF polypeptides and methods of producing same
|
US8324159B2
(en)
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
WO2006134173A2
(en)
*
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
ES2341285T3
(es)
*
|
2005-07-19 |
2010-06-17 |
Nektar Therapeutics |
Metodo para preparar maleimidas polimericas.
|
AU2006278490A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics |
Conjugates of a G-CSF moiety and a polymer
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
CN102719508A
(zh)
*
|
2005-08-19 |
2012-10-10 |
诺和诺德公司 |
糖基聚乙二醇化的因子vii和因子viia
|
WO2007041614A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Bolder Biotechnology, Inc. |
Long acting vegf inhibitors and methods of use
|
US20070160658A1
(en)
*
|
2005-10-20 |
2007-07-12 |
The Penn State Research Foundation |
Delivery system for diagnostic and therapeutic agents
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP2213733A3
(de)
*
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Analoge des Faktor IX mit verlängerter Halbwertszeit in vivo
|
US7534595B2
(en)
*
|
2006-06-12 |
2009-05-19 |
Biomarin Pharmaceutical Inc. |
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
|
US7531341B1
(en)
|
2006-06-12 |
2009-05-12 |
Biomarin Pharmaceutical Inc. |
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
|
EP2049144B8
(de)
|
2006-07-21 |
2015-02-18 |
ratiopharm GmbH |
Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
|
KR20090046923A
(ko)
|
2006-08-04 |
2009-05-11 |
프로롱 파마슈티컬스, 인크. |
수식된 에리스로포이에틴
|
JPWO2008023725A1
(ja)
|
2006-08-22 |
2010-01-14 |
中外製薬株式会社 |
末梢神経障害の予防および/または治療剤
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
US7803769B2
(en)
*
|
2006-10-25 |
2010-09-28 |
Amgen Inc. |
OSK1 peptide analogs and pharmaceutical compositions
|
US8617531B2
(en)
|
2006-12-14 |
2013-12-31 |
Bolder Biotechnology, Inc. |
Methods of making proteins and peptides containing a single free cysteine
|
US8389482B2
(en)
|
2007-01-30 |
2013-03-05 |
New York University |
Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
|
US8106154B2
(en)
|
2007-01-31 |
2012-01-31 |
Affymax, Inc. |
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
EP2144923B1
(de)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Behandlungsverfahren mit glycopegyliertem g-csf
|
AU2008262490B2
(en)
|
2007-05-22 |
2011-11-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
EP2578677A1
(de)
|
2007-08-09 |
2013-04-10 |
Genzyme Corporation |
Verfahren zur Behandlung von Autoimmunerkrankungen mit mesenchymalen Stammzellen
|
US7537923B2
(en)
*
|
2007-08-17 |
2009-05-26 |
Biomarin Pharmaceutical Inc. |
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
|
US8758761B2
(en)
|
2007-09-30 |
2014-06-24 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
US8106160B2
(en)
*
|
2007-10-01 |
2012-01-31 |
Pharmaessentia Corp. |
N-terminal modified interferon-alpha
|
KR101486449B1
(ko)
|
2008-01-11 |
2015-01-26 |
세리나 쎄라퓨틱스, 인코포레이티드 |
다작용성 형태의 폴리옥시졸린 공중합체 및 이를 포함하는 약물 조성물
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
US20110201022A1
(en)
|
2008-07-30 |
2011-08-18 |
Biomarin Pharmaceutical Inc. |
Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
|
US20110318322A1
(en)
|
2009-01-12 |
2011-12-29 |
Nektar Therapeutics |
Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
HUE039516T2
(hu)
|
2010-02-04 |
2019-01-28 |
Biomarin Pharm Inc |
Eljárás prokarióta fenilalanin-liáz variánsok tisztítására
|
US9187543B2
(en)
|
2010-03-04 |
2015-11-17 |
Pfenex Inc. |
Method for producing soluble recombinant interferon protein without denaturing
|
AU2011235210B2
(en)
|
2010-04-01 |
2015-07-16 |
Pfenex Inc. |
Methods for G-CSF production in a Pseudomonas host cell
|
MX349054B
(es)
|
2010-09-28 |
2017-07-07 |
Aegerion Pharmaceuticals Inc |
Leptinas altamente solubles.
|
KR102591732B1
(ko)
|
2010-11-12 |
2023-10-19 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
EA201391331A1
(ru)
|
2011-03-16 |
2014-02-28 |
Эмджен Инк. |
Активные и селективные ингибиторы nav1.3 и nav1.7
|
WO2013020079A2
(en)
|
2011-08-04 |
2013-02-07 |
Nektar Therapeutics |
Conjugates of an il-11 moiety and a polymer
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
WO2014165277A2
(en)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
POTENT AND SELECTIVE INHIBITORS OF Nav1.7
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
SG11201600954XA
(en)
|
2013-10-15 |
2016-03-30 |
Seattle Genetics Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
MA39711A
(fr)
|
2014-04-03 |
2015-10-08 |
Nektar Therapeutics |
Conjugués d'une fraction d'il-15 et d'un polymère
|
SG11201608868PA
(en)
|
2014-05-01 |
2016-11-29 |
Genentech Inc |
Anti-factor d antibody variants and uses thereof
|
JP6803236B2
(ja)
|
2014-06-10 |
2020-12-23 |
アムジェン インコーポレイテッド |
アペリンポリペプチド
|
EP3368090A1
(de)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
JP2019501131A
(ja)
|
2015-12-04 |
2019-01-17 |
シアトル ジェネティックス, インコーポレイテッド |
四級化チューブリシン化合物の複合体
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
WO2018175994A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US20230158141A1
(en)
*
|
2017-11-08 |
2023-05-25 |
Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd |
Conjugates of Biomolecule and Use Thereof
|
WO2019130344A1
(en)
|
2017-12-27 |
2019-07-04 |
Council Of Scientific And Industrial Research |
A polypeptide exhibiting granulocyte-colony stimulating factor activity
|
EP3797752A4
(de)
|
2018-05-21 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
In einem glasfläschchen verschlossene lyophilisierte formulierung
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
CN114929284A
(zh)
|
2019-10-04 |
2022-08-19 |
西根公司 |
喜树碱肽缀合物
|
TW202144419A
(zh)
|
2020-03-24 |
2021-12-01 |
美商建南德克公司 |
Tie2結合劑及其使用方法
|
KR20230008723A
(ko)
|
2020-04-10 |
2023-01-16 |
씨젠 인크. |
전하 변이체 링커
|
JP2024503508A
(ja)
|
2021-01-15 |
2024-01-25 |
シージェン インコーポレイテッド |
免疫調節性抗体-薬物コンジュゲート
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
AR124812A1
(es)
|
2021-02-03 |
2023-05-10 |
Seagen Inc |
Conjugados y compuestos inmunoestimulantes
|
CN117580593A
(zh)
|
2021-05-28 |
2024-02-20 |
思进公司 |
蒽环霉素抗体结合物
|
US20230381321A1
(en)
|
2022-03-17 |
2023-11-30 |
Seagan Inc., |
Camptothecin conjugates
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
EP4321522A1
(de)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Zytotoxische verbindungen und konjugate davon
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|